SERPINA1 and benign prostatic hyperplasia: Preliminary data for compound 9 are promising enough to warrant its further detailed mechanistic studies as a potential uroselective α1A- and α1D-AR antagonist in the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.